An international buyer cannot approve Abirakast 250 from the brand name and tablet strength alone. You need to confirm the active ingredient, registration pathway, prescribing conditions, pack configuration, quality documents, and shipping controls before comparing an export quotation.
Key takeaways
- Confirm the active ingredient, dosage form, manufacturer and registration status.
- Match 250 mg tablets to the prescriber’s complete abiraterone regimen.
- Request batch documents, stability data and safety information before ordering.
- Specify quantity, Incoterms, destination and required export documents in the quotation.
How do you verify what Abirakast 250 actually is?
Resolve identity before discussing price or volume. Abirakast 250 is a product name, not the internationally standardized substance name, and its brand name does not prove registration in your country.
1. Ask the abirakast 250 pharmaceutical exporter to provide the approved label and confirm that it states “abiraterone acetate 250 mg per tablet.” Record the dosage form, tablet appearance, manufacturer, manufacturing site, country of origin, and whether the medicine is a generic equivalent or a branded product.
2. Request the destination-country marketing authorization number, registration certificate, or documented import-permit route. Registration in another country does not establish permission to sell in your market.
3. Check that the legal manufacturer, marketing authorization holder, and exporter named on those documents match the quotation. Resolve any mismatch before reviewing pack size or shipment volume.
4. Create an abirakast 250 pharmaceutical exporter due-diligence file containing the approved product information, product specification, stability data, and proposed local label. Keep the registration evidence with it.
5. Pause the order if the supplier cannot identify the active ingredient in exact regulatory wording or provides only a catalogue page. A certificate of analysis confirms that a batch was tested; it does not authorize sale in your market.
How is the 250 mg strength used in the prescribed regimen?
For normal hepatic function, the usual adult regimen is 1,000 mg once daily: four 250 mg tablets, not one tablet as a complete daily treatment. Abiraterone acetate inhibits CYP17 to suppress androgen production and is used with androgen-deprivation treatment for approved advanced prostate-cancer regimens, not as stand-alone chemotherapy.
1. Confirm the accompanying corticosteroid. The prescriber uses prednisone or prednisolone according to the approved indication and the patient’s clinical factors. An abiraterone 250mg distributor must show that regimen in professional documentation rather than presenting the tablets alone.
2. Give the administration instruction exactly: swallow the tablets whole on an empty stomach, at least one hour before food or two hours after food. Food can sharply increase exposure; a high-fat meal has been reported to increase abiraterone exposure by approximately 10-fold and peak concentration by 17-fold.
Therefore, “take with food” in an abirakast 250 wholesale listing is a clinically important error.
3. Do not convert the 250 mg strength into a universal liver-impairment dose. US prescribing information uses 250 mg once daily as the reduced starting dose for moderate hepatic impairment and does not recommend abiraterone acetate in severe hepatic impairment.
4. Direct every treatment decision to the prescriber. The tablet count, corticosteroid, fasting schedule, and dose for liver impairment must follow the approved product information and the individual patient’s assessment.
What safety information must accompany an abiraterone order?
A safe abiraterone 250mg distributor file must accompany the shipment with professional product information, not a tablet price alone. State abiraterone acetate 250 mg per tablet, the approved indication, corticosteroid regimen, fasting instructions, interaction warnings, monitoring schedule, and the rule against substituting another strength or product without prescriber approval.
1. Explain that CYP17 inhibition suppresses cortisol and can cause mineralocorticoid excess: hypertension, low serum potassium, and fluid retention. Monitor blood pressure, serum potassium, and fluid-retention symptoms at least monthly. Include prednisone or prednisolone requirements and the treatment team’s monitoring plan.
2. Provide the liver-monitoring schedule: check ALT, AST, and bilirubin before treatment and during treatment. Under US prescribing information, interrupt treatment for ALT or AST above 5 times the upper limit of normal, or bilirubin above 3 times that limit.
Resume at 750 mg once daily after recovery; reduce to 500 mg if toxicity recurs, and discontinue after recurrence at 500 mg. Permanently discontinue concurrent ALT above 3 times normal with bilirubin above 2 times normal when other causes are excluded.
3. Ask the importer to review liver disease, uncontrolled hypertension, cardiovascular risk, adrenal insufficiency, and medicines. Strong CYP3A4 inducers reduce exposure; abiraterone affects CYP2D6- and CYP2C8-metabolized medicines.
Warehouse procedures must prevent pregnant people from handling uncoated, broken, or crushed tablets without protective measures. Quarantine damaged packs, record the incident, and define release, return, or destruction before receiving stock.
What should you compare before choosing a 250 mg prostate-cancer product?
Compare treatment suitability and supply specifications, not pack prices alone. Enzalutamide, apalutamide, and darolutamide are androgen-receptor pathway medicines, while abiraterone acetate inhibits CYP17; their indications, evidence, administration, monitoring, and interaction risks differ.
| Product | Approved-use and evidence check | Administration and monitoring |
|---|---|---|
| Abiraterone acetate 250 mg | Approved regimen and clinical evidence for the patient’s disease stage | Four 250 mg tablets may make a 1,000 mg daily dose; take fasting with a corticosteroid; monitor liver function, blood pressure, potassium, and fluid retention |
| Enzalutamide | Confirm its approved indication and supporting clinical evidence | Different dosage form and interaction profile; no abiraterone fasting or corticosteroid regimen |
| Apalutamide | Confirm indication and evidence for the proposed treatment | Different administration, contraindications, monitoring, and interaction profile |
| Darolutamide | Confirm indication and evidence, including combination requirements | Different dosing, food instructions, and interaction profile |
For an abirakast 250 wholesale quotation, request tablets per blister or bottle, blisters or bottles per carton, primary and secondary packaging materials, batch size or standard manufacturing lot, shelf life at release, expiry-date format, and tamper-evident features. Ask whether it is the same registered generic presentation as a local product or a new registration.
Compare price per prescribed treatment day, not price per tablet. Confirm storage against the approved label: the US label specifies 20–25 °C controlled room temperature, with excursions from 15–30 °C. A credible abirakast 250 export supplier must define temperature evidence, quarantine, and final disposition in the quality agreement.
What must an international distributor request in the export quotation?
A quotation is incomplete if it names Abirakast 250 but cannot identify the shipment, seller, and regulatory route. Ask the abirakast 250 pharmaceutical exporter to state these details before you compare price or approve a purchase order.
| Quotation field | What to require | Why it matters |
|---|---|---|
| Exporting party | Legal entity, India-origin country, Importer Exporter Code or applicable exemption | Confirms who is legally exporting |
| Product and market | Manufacturer, marketing authorization holder, destination market, quantity, pack size, minimum order quantity | Prevents a product name from replacing market-specific authorization |
| Release and delivery | Batch-release arrangement, remaining shelf-life commitment, Incoterm, freight responsibility, and responsibility for import clearance | Assigns custody, cost, and border obligations |
| Shipment records | Invoice, packing list, batch number, expiry date, and matching quantities | Lets customs and your receiving team reconcile the load |
Request the following supporting package:
- Batch certificate of analysis, approved specification, product information, stability summary, manufacturing-site GMP evidence, and packaging artwork.
- Approved shipping-temperature range and monitoring evidence; use the product label and stability data rather than assuming ambient transport is safe.
- Adverse-event reporting contact and process, plus a WHO Certificate of Pharmaceutical Product if the destination authority accepts it. The importing regulator decides whether that certificate is sufficient.
The quality agreement should assign rejected-goods handling, recalls, complaints, temperature excursions, and pharmacovigilance contacts. NIBA HEALTHCARE can make its distributor documentation useful by mapping each Abirakast 250 wholesale enquiry to these documents and responsibilities. A professional abirakast 250 export supplier will also define the India-export paperwork before dispatch.
Related products
![]() | ABIRATERONE TABLET Abirakast 250mg Tablet is used in the treatment of cancer of the prostate gland. View product → |
![]() | ABIRATERONE TABLET Tablet is used in the treatment of cancer of the prostate gland. It may be also used to treat other conditions, as determined by the doctor. View product → |
Frequently asked questions
How do you verify what Abirakast 250 actually is?
Check the pack, product information and manufacturer documents for the active ingredient, dosage form, strength, batch number, expiry date and registration status. Treat Abirakast 250 as a brand name until those details confirm its identity.
How is the 250 mg strength used in the prescribed regimen?
A 250 mg tablet strength must be assessed against the prescribed abiraterone regimen, administration instructions and required accompanying medicines. Do not infer the patient’s dose from the brand name alone; confirm the approved product information and prescriber’s instructions.
What safety information must accompany an abiraterone order?
Request the approved product information, patient or professional safety information, storage requirements, contraindications, warnings, interaction information and batch-specific quality documents. Check that the documents match the exact manufacturer, strength and dosage form.
What should you compare before choosing a 250 mg prostate-cancer product?
Compare the active ingredient and form, regulatory status in the destination market, manufacturer, pack configuration, shelf life, storage conditions, batch-release evidence, traceability and total landed cost—not price alone.
What must an international distributor request in the export quotation?
Ask for the exact product description, strength, dosage form, pack size, available quantity, batch and expiry information, certificate documents, shipping terms, destination requirements, lead time, payment terms and quotation validity.

